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Results: The mean age (±SD) of patients was
7.31± 10.65 years, 83% of them being female, and
4 out of 41 (34%) patients were in an active phase of
he disease. ASCA IgG levels signiﬁcantly were correlated
ith sypmtom duration x disease extension score factorial
r = 0.481, p = 0.001), disease duration x disease extension
core factorial (r = 0.468, p = 0.002), and SES-CD (r = 0.480,
= 0.001). No correlations were noted between ASCA
nd CRP levels and clinical activity. On age-sex adjusted
tepwise regression analysis, sypmtom duration, disease
uration, disease extension, and SES-CD entered into
he model, disease extension score was found to be the
nly independent predictor of ASCA IgG levels (R2 = 0.1,
= 0.044).
Conclusion: Although the aetiopathogenesis of inﬂam-
atory bowel disease remains unsolved, a serologic
nti-microbial response exists one of them being ASCA. Dis-
ase and symptom duration, disease extension but clinical
ctivity have signiﬁcant correlations with ASCA levels point-
ng out to the importance of sustained immunological stimuli
s a triggering process. These results might provide new
nsights into the mechanisms of epithelial responses to anti-
ens and ideas for therapies.
oi:10.1016/j.ijid.2010.02.1746
0.006
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Background: The role of perinuclear antineutrophil
ytoplasmic antibodies (pANCA) and anti-Saccharomyces
erevisiae antibodies (ASCA) assessment in inﬂammatory
owel disease (IBD) diagnosis and differentiating is still
mprecise and controversial.
Methods: The aim of the study was to determine the
ccuracy of pANCA and ASCA in patients with speciﬁc intesti-
al inﬂammations, namely UC, CD, GI Behcet (GI-BD), GI
uberculosis (GI-TBC) which are under the same inﬂam-
atory bowel registry, compared to tree control groups;
amely, Celiac disease, irritable bowel syndrome (IBS)
atients and healthy controls (HC). A total of 493 subjects
102 with UC, 63 with CD, 13 with GI BD, 10 with GI Tb, 130
ith IBS, 10 with Celiac disease, and 165 HC) ﬁrstly admitted
o our weekly IBD outpatient practice of a tertiary referral
enter were analyzed regarding pANCA and ASCA Ig A-G via
mmunoﬂuorescent assay (IFA) with commercially available
FA kits (Euroimmune, Lübeck, Germany).
Results: The prevalence of any pANCA or ASCA positiv-
ty and age and sex of patients are summarized in Table 1.
n UC patients the prevalence of pANCA was 42.2%, which
as signiﬁcantly higher than in CD-4.8% (p = 0.000). ASCA
as found signiﬁcantly more often in CD-54% than in UC
(
a
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atients-4.8% (p = 0.000). The prevalence of ASCA in BD
atients-15.4% disclosed a signiﬁcant difference compared
o CD patients (p = 0.014), but the prevalence of ASCA in TBC
atients showed no signiﬁcant difference compared to CD or
D patients.
Table 1: Prevalence of pANCA and ASCA in different sub-
roups.Marked values(p < .05)
pANCA(+) ASCA(+) age male(%)
BS (n = 130) 1(0.8%) 4(3.07%) 40.84(SD 12.69)* 42.3(a)
C (n = 165) 1(0.6%) 7(4.2%) 35.07(SD 10.49)*;** 40(b)
C (n = 102) 43 (42.2%) 11(10.8%) 40.72(SD 13.44)** 50(c)
D (n = 63) 3 (4.8%) 34(54%) 37.56(SD 12.65) 38.1(d)
I-BD (n = 13) 0 2(15.4%) 32.11(SD 8.89) 61(e)
eliac Disease (n = 10) 0 4(40%) 36.77(SD 7.94) 0(a;b;c;d;e;f)
I-TBC (n = 10) 1(10%) 3(30%) (SD 9.96) 70(f)
Conclusion: Our results conﬁrm that in clinical practice
SCA is not speciﬁc enough to be a useful tool in differential
iagnosis of any speciﬁc inﬂammation. However, it may have
ome value in screening of normal population for any bowel
nﬂammation. pANCA may have a better clinical value in the
iscrimination of UC from other intestinal inﬂammations.
oi:10.1016/j.ijid.2010.02.1747
0.007
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Background: Pentamycin is a broad-spectrum polyene
acrolide and the available intravaginal formulation
FemiFect®, 3mg vaginal tablets, Lumavita AG, Basel,
witzerland) is effective in the treatment of vaginal tri-
homoniasis, candidiasis sustained by Candida albicans and
ixed infections (Clin. Ter. 92: 137-142, 1980; Internet Jour-
al of Gynecology and Obstetrics 11(1), 2009). Because
easts other than C. albicans are frequently isolated in
ecurrent or mixed forms of vaginal mycoses, it is impor-
ant to assess the activity of pentamycin against these
pecies, which also exhibit reduced susceptibility to conven-
ional antimycotic drugs. Therefore, the objective of this
tudy was to compare the in-vitro activity of pentamycin
ith that of nystatin, amphotericin B, and ﬂuconazole
gainst strains of nonalbicans candidal species and strains of
accharomyces cerevisiae isolated from medical samples.
Methods: Two collections of clinical isolates included in
otal 40 strains of C. glabrata, 41 strains of C. parapsilo-
is, 30 strains of C. tropicalis, 30 strains of C. krusei and
0 strains of S. cerevisiae. In-vitro susceptibility testing was
erformed using the broth microdilution method developed
y the Clinical and Laboratory Standards Institute (CLSI),
ocument M27-A2. The minimal inhibitory concentration
MIC) of each tested drug was read visually after 24 hours
nd 48 hours of incubation.
Results: The MIC at which 90% of strains of each yeast
pecies were inhibited (MIC90) after 48 hours of incubation
